Development asset linked to Xeris Biopharma Holdings in public FDA and regional records.
biotech · Hypoglycemia · Diabetes Mellitus, Type 1 · XERS
Xeris Biopharma Holdings
Xeris Biopharma Holdings drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Chicago, USA HQ
2005 Founded
496 Employees
Public company Type
XERS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Chicago, USA
- Founded
- 2005
- Employees
- 496
- Programs
- 16
- Drugs
- 12
- Patents
- 24
Xeris Biopharma Holdings pipeline
Portfolio lens on 12 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Xeris Biopharma Holdings drug portfolio — 12 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Carbonic anhydrase 1.
- Target
- Carbonic anhydrase 1
- Mechanism
- Carbonic anhydrase XII inhibitor
-
Development asset linked to Xeris Biopharma Holdings in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucagon receptor.
- Target
- Glucagon receptor
- Mechanism
- Glucagon receptor agonist
-
Development asset linked to Xeris Biopharma Holdings in public FDA and regional records.
-
Development asset linked to Xeris Biopharma Holdings in public FDA and regional records.
-
Development asset linked to Xeris Biopharma Holdings in public FDA and regional records. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to Xeris Biopharma Holdings in public FDA and regional records. Mechanism: Thyroid hormone receptor agonist.
- Mechanism
- Thyroid hormone receptor agonist
-
US regulatory status: approved. Molecular target: Thyroid hormone receptor.
- Target
- Thyroid hormone receptor
- Mechanism
- Thyroid hormone receptor agonist
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
US regulatory status: approved.